EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access

Germline Pathogenic Variants Among Women Without a History of Breast Cancer

Kirkpatrick B Fergus, Katherine S Ross, Maren T Scheuner, Amie M Blanco, Jeffrey A Tice, Elad Ziv, Yiwey Shieh, Laura van 't Veer, Olufunmilayo I Olopade, Deborah L Goodman, Barry S Tong, Heather Harvey und 25 weitere

JAMA Internal Medicine · 01.03.2026 · 186 (3) · 344

DOI: 10.1001/jamainternmed.2025.7323 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.03.2026. Verfasst von Kirkpatrick B Fergus und 36 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genetics and Prevention Program, University of California, San Francisco. Hauptthemen laut MEDLINE: Breast Neoplasms, Germ-Line Mutation, Genetic Predisposition to Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The prevalence of pathogenic or likely pathogenic variants (PVs) in breast cancer susceptibility genes in the US population—regardless of family history risk factors—remains largely unknown because population-based genetic screening is not routinely performed.

Objective

To identify the prevalence of PVs in a large cohort of women offered criteria-independent genetic testing and to evaluate the relationship of test positivity to family history and other patient characteristics. Design, Setting, and Participants The Women Informed to Screen Depending on Measures of Risk (WISDOM) randomized clinical trial enrolled women without breast cancer aged 40 to 74 years between August 2016 and February 2023 in a pragmatic randomized screening trial comparing annual screening mammography with personalized risk-based screening. Data were analyzed from August 2023 to November 2025. Exposures All women in the personalized screening arm were offered germline testing for 9 breast cancer susceptibility genes: BRCA1 , BRCA2 , ATM , CHEK2 , PALB2 , CDH1 , PTEN , STK11 , and TP53 . Main Outcomes and Measures The prevalence of PVs in the trial and the distribution of self-reported demographic and family history data in this subpopulation of carriers.

Results

Among 23 098 women who completed germline genetic testing (mean [SD] age, 54.3 [9.6] years), 714 (3.1%) carried a PV. Excluding 109 who were previously aware of their PV, the detection rate was 2.6%. PVs were most common in CHEK2 (337 [1.5%]) and ATM (101 [0.4%]) but less common in higher-penetrance genes ( BRCA1 , 33 [0.1%]; BRCA2 , 82 [0.4%]; PALB2 , 44 [0.2%]). PVs in the CDH1 , PTEN , STK11 , and TP53 genes were rare (less than 0.1%). Notably, 180 of 605 women with PVs (29.8%) did not report a first-degree or second-degree female relative with breast or ovarian cancer, male relative with breast cancer, or Jewish ancestry. Conclusions and Relevance In this secondary analysis of the WISDOM trial, criteria-independent genetic testing in a pragmatic trial identified a substantial number of women with clinically actionable results, many of whom would not have qualified for genetic testing under current guidelines. These findings support broader access to genetic testing as part of personalized breast cancer risk assessment. Trial Registration ClinicalTrials.gov Identifier: NCT02620852

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGerm-Line MutationGenetic Predisposition to DiseaseHumansFemaleMiddle AgedAdultAgedGenetic TestingEarly Detection of CancerBRCA1 ProteinMammography

Substanzen

BRCA1 Protein

Autor:innen und Institutionen

  • Cancer Genetics and Prevention Program, University of California, San Francisco.
  • San Francisco VA Health Care System, San Francisco, California.
  • Department of Medicine/Hematology-Oncology, University of California, San Francisco.
  • Department of Pediatrics/Medical Genetics, University of California, San Francisco.
  • Division of General Internal Medicine, Department of Medicine, University of California, San Francisco.
  • Department of Population Health Sciences, Weill Cornell Medicine, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

Fergus, K. B., Ross, K. S., Scheuner, M. T., Blanco, A. M., Tice, J. A., Ziv, E., Shieh, Y., van 't Veer, L., Olopade, O. I., Goodman, D. L., Tong, B. S., Harvey, H., DeRosa, D., Risty, L., Silver, E., Kaster, A., Fiscalini, A. S., Blum, K., Heise, R., …, & Madlensky, L. (2026). Germline Pathogenic Variants Among Women Without a History of Breast Cancer. JAMA Internal Medicine, 186(3), 344. https://doi.org/10.1001/jamainternmed.2025.7323

Vancouver

Fergus KB, Ross KS, Scheuner MT, Blanco AM, Tice JA, Ziv E, et al. Germline Pathogenic Variants Among Women Without a History of Breast Cancer. JAMA Internal Medicine. 2026;186(3):344. doi:10.1001/jamainternmed.2025.7323

BibTeX
@article{Fergus2026,
  author = {Fergus, Kirkpatrick B and Ross, Katherine S and Scheuner, Maren T and Blanco, Amie M and Tice, Jeffrey A and Ziv, Elad and Shieh, Yiwey and van 't Veer, Laura and Olopade, Olufunmilayo I and Goodman, Deborah L and Tong, Barry S and Harvey, Heather and DeRosa, Diana and Risty, Larissa and Silver, Erica and Kaster, Andrea and Fiscalini, Allison Stover and Blum, Kelly and Heise, Rachel and Sabacan, Leah and Heditsian, Diane and Brain, Susie and Petruse, Antonia and Eklund, Martin and Hiatt, Robert A and Borowsky, Alexander D and Naeim, Arash and Park, Hannah L and LaCroix, Andrea Z and Parker, Barbara A and Lancaster, Rachael and Esserman, James and Wenger, Neil and Arasu, Vignesh and Anton-Culver, Hoda and Esserman, Laura J and Madlensky, Lisa},
  title = {Germline Pathogenic Variants Among Women Without a History of Breast Cancer},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {3},
  pages = {344},
  doi = {10.1001/jamainternmed.2025.7323}
}
Kostenlos starten →